Table 2.
KEGG pathway analysis of DEGs associated with seminoma
| Expression | Pathway ID | Term | Count | % | P-value | FDR | Genes |
|---|---|---|---|---|---|---|---|
| Up-regulated | hsa04060 | Cytokine−cytokine receptor interaction | 44 | 7.73 | 5.35E−15 | 6.77E-12 | IL1R2, CCL3, CCL2, PDGFB, TNFRSF25, CCR1, CXCL9, FASLG, CCL8, KIT, CCL5, CXCL11, CCL4, TNFRSF4, IL10, FLT3LG, CXCL10, TNFRSF1B, TNFRSF11B, IL23A, CXCR5, CXCR4, IFNA5, IL10RA, CXCR6, IFNG, CSF2RB, IL1B, IL2RG, LTB, CSF2RA, CD27, IL6, IL2RB, CCL19, IL6R, IFNAR2, CCR8, TNFSF10, CCR5, CXCL13, CCR2, VEGFA, ACVR1 |
| hsa04514 | Cell adhesion molecules (CAMs) | 27 | 4.75 | 2.78E−09 | 3.54E−06 | ITGAL, CLDN7, CD8A, CDH1, L1CAM, ITGB2, HLA-DMB, CDH3, HLA-DMA, ITGAM, NRCAM, CD2, HLA-DRB4, CD4, HLA-DPB1, HLA-DOA, CD28, ICAM1, PTPRC, SELL, ICAM2, ITGA4, HLA-E, HLA-F, PECAM1, HLA-DPA1, HLA-DRA | |
| hsa04145 | Phagosome | 28 | 4.92 | 3.17E−09 | 4.03E−06 | TUBB2B, TLR2, ITGB2, HLA-DMB, ATP6V1B1, HLA-DMA, ITGAM, TUBB, TAP2, HLA-DRB4, HLA-DPB1, FCGR3A, THBS1, HLA-DOA, FCGR3B, NCF2, NCF4, CTSS, HLA-E, HLA-F, CYBA, CORO1A, CYBB, ITGA5, HLA-DPA1, FCGR2A, CD14, HLA-DRA | |
| hsa04380 | Osteoclast differentiation | 25 | 4.39 | 1.15E−08 | 1.46E−05 | NCF2, NCF4, ACP5, NFKB2, STAT1, JUNB, BTK, STAT2, LILRB1, IRF9, IFNAR2, LILRB2, CYBA, TNFRSF11B, CYBB, LILRB3, LCK, IFNG, LILRB4, IL1B, FCGR2A, FCGR3A, FCGR3B, TYROBP, LCP2 | |
| hsa04670 | Leukocyte transendothelial migration | 22 | 3.87 | 1.63E−07 | 2.07E−04 | ICAM1, ITGAL, CLDN7, MYL7, ITK, NCF2, MMP9, NCF4, SIPA1, ACTN1, ITGB2, ITGA4, ITGAM, VASP, THY1, CYBA, CYBB, RAC2, CXCR4, PECAM1, MSN, RHOH | |
| hsa04650 | Natural killer cell mediated cytotoxicity | 22 | 3.87 | 2.94E−07 | 3.73E−04 | ICAM1, ITGAL, PTPN6, ICAM2, CD247, FASLG, ITGB2, GZMB, NCR1, CD48, IFNAR2, TNFSF10, SH2D1A, RAC2, IFNA5, LCK, IFNG, FCER1G, FCGR3A, FCGR3B, TYROBP, LCP2 | |
| hsa04062 | Chemokine signaling pathway | 27 | 4.75 | 8.07E−07 | 1.03E−03 | CCL3, CCL2, CCR1, CXCL9, CCL8, CXCL11, CCL5, CCL4, CXCL10, RAC2, CXCR5, CXCR4, CXCR6, ITK, LYN, HCK, CCL19, STAT1, CCL18, STAT2, CCR8, CCR5, ARRB2, CXCL13, CCR2, GRK5, XCL2 | |
| hsa04612 | Antigen processing and presentation | 16 | 2.81 | 2.59E−06 | 3.29E−03 | CD8A, CTSS, HLA-DMB, HLA-E, HLA-DMA, CD74, HLA-F, B2M, TAP2, IFNG, HLA-DRB4, CD4, HLA-DPA1, HLA-DPB1, HLA-DOA, HLA-DRA | |
| Down-regulated | hsa04530 | Tight junction | 17 | 2.23 | 5.54E−04 | 7.16E−01 | PPP2R1B, PRKCZ, CLDN18, MYL5, MAGI1, GNAI1, MYH3, MYLPF, MYH7, ACTN3, CTNNA2, CSNK2A2, EPB41L3, MYH11, EXOC3, TJP3, TJP2 |
| hsa00620 | Pyruvate metabolism | 8 | 1.05 | 2.13E−03 | 2.73E+00 | HAGH, LDHC, ME1, ME3, ACYP1, PDHA2, ACACB, PC | |
| hsa04110 | Cell cycle | 14 | 1.84 | 4.68E−03 | 5.90E+00 | CCNE2, CDKN1C, E2F2, FZR1, CDKN1B, RBL2, CDKN2B, CCNH, DBF4, CDKN2D, CDK6, PTTG1, CDC25C, CCNA1 | |
| hsa04724 | Glutamatergic synapse | 12 | 1.57 | 1.61E−02 | 1.90E+01 | PRKACG, SLC1A2, DLGAP1, GNAO1, GRIA2, ADCY9, GNAI1, GRM8, SLC1A6, PPP3CC, CACNA1C, GRK3 | |
| hsa01100 | Metabolic pathways | 72 | 9.45 | 2.27E−02 | 2.58E+01 | LDHC, KYNU, CYP2J2, PGAM2, ITPKA, CKB, AKR1C3, TYR, AKR1C4, AGPS, PTGES, RGN, PDHA2, PCYT2, NT5E, NMNAT2, DDC, ALDH6A1, HYAL3, PDXK, GATM, CYP11A1, PFKP, CDS1, GMPS, NME5, ALOX15, ADO, PTGDS, CHPF, RFK, ABAT, PLA2G6, INPP4B, INPP1, GALNT3, ME1, CHKA, ME3, MVD, GK2, HMGCS1, HPRT1, ALDH1A1, TYMS, CKMT2, PLCH1, HSD17B3, PLCD1, PCYT1B, PRPS1L1, UGT8, MTMR6, SPAM1, GAD1, ODC1, PLA2G16, UAP1, SPHK2, MAOA, BCKDHB, MGAT4C, SI, ACACB, GAPDHS, CYP17A1, ACSM1, PYGM, HMGCS2, GAMT, PC, LIPF | |
| hsa04913 | Ovarian steroidogenesis | 7 | 0.92 | 2.46E−02 | 2.76E+01 | AKR1C3, PRKACG, CYP17A1, CYP2J2, ADCY9, CYP11A1, STAR | |
| hsa04360 | Axon guidance | 12 | 1.57 | 3.29E−02 | 3.52E+01 | EPHA5, DCC, EPHA4, PAK3, GNAI1, ROBO1, EFNB2, SEMA3D, SRGAP3, PPP3CC, SEMA3C, EPHB1 | |
| hsa04020 | Calcium signaling pathway | 15 | 1.97 | 3.76E−02 | 3.92E+01 | SPHK2EPHB1 ERBB4, SLC25A4, PHKG2, ITPKA, PRKACG, CAMK4, ADCY9, PLN, PDE1A, PPP3CC, PLCD1, CACNA1C, MYLK, HTR2A |